Liu Ying, Ma Yue, Zhou Huihui, Zhou Xiuzhi, Shao Juan
Department of Oncology, Pathology and Dermatology, Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China.
Department of Urology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China.
Oncol Lett. 2020 Oct;20(4):43. doi: 10.3892/ol.2020.11908. Epub 2020 Jul 24.
Non-Hodgkin's intravascular large B-cell lymphoma is a highly invasive extranodal lymphoma. The proliferating tumor cells invade the small vessels and capillaries of different organs. The clinical symptoms are atypical, there is lack of specificity, and the molecular and biological behaviors are not clear, thus, the present study aimed to improve the current understanding of non-Hodgkin's intravascular large B-cell lymphoma (IVL) and provide an accurate basis for clinical treatment and prognosis, by retrospectively analyzing and summarizing the clinicopathological features, immunohistochemical findings and molecular characteristics of 17 patients with IVL. The Kaplan-Meier method and log rank test were implemented to determine survival outcomes. Fisher's exact test was used to determine the association between clinicopathological features and the expression levels of Ki-67, c-Myc, B-cell lymphoma 6 (Bcl-6) and B-cell lymphoma 2 (Bcl-2), while multivariate Cox regression analysis was performed to identify the independent risk factors that affect the survival rates of patients with IVL. P<0.05 was considered to indicate a statistically significant difference. Among the 17 patients with IVL, 13 cases (76.47%) occurred in the adrenal gland and four cases (23.53%) occurred on the skin demonstrated positive IgH gene rearrangement. FISH analysis indicated that cleavage of the c-Myc gene was closely associated with sex, hypertension status and tumor size, while cleavage of the Bcl-6 gene was closely associated with tumor size parameters. Overall, the results suggest that the Ki-67 proliferation index is an independent risk factor for the prognosis (survival time) of patients with IVL.
非霍奇金血管内大B细胞淋巴瘤是一种侵袭性很强的结外淋巴瘤。增殖的肿瘤细胞侵犯不同器官的小血管和毛细血管。临床症状不典型,缺乏特异性,分子生物学行为尚不清楚,因此,本研究旨在通过回顾性分析和总结17例血管内大B细胞淋巴瘤(IVL)患者的临床病理特征、免疫组化结果及分子特征,提高对非霍奇金血管内大B细胞淋巴瘤的当前认识,并为临床治疗和预后提供准确依据。采用Kaplan-Meier法和对数秩检验确定生存结果。采用Fisher确切检验确定临床病理特征与Ki-67、c-Myc、B细胞淋巴瘤6(Bcl-6)和B细胞淋巴瘤2(Bcl-2)表达水平之间的关联,同时进行多因素Cox回归分析以确定影响IVL患者生存率的独立危险因素。P<0.05被认为具有统计学显著差异。在17例IVL患者中,13例(76.47%)发生于肾上腺,4例(23.53%)发生于皮肤,均显示IgH基因重排阳性。FISH分析表明,c-Myc基因的断裂与性别、高血压状态和肿瘤大小密切相关,而Bcl-6基因的断裂与肿瘤大小参数密切相关。总体而言,结果表明Ki-67增殖指数是IVL患者预后(生存时间)的独立危险因素。